

Bulletin #100

Tiered Biologics Reimbursement Policy

Effective August 15, 2018

- Effective August 15, 2018, Manitoba Health, Seniors and Active Living will be implementing a Tiered Biologics Reimbursement Policy.
- This Policy will ONLY apply to New Patients (biologic naïve) and Existing Patients that have previously been trialed and deemed unresponsive to biologic therapy as follows:
 - New Patients (biologic-naïve);
 - Select product from Tier 1 → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)
 - Existing Patients (ONLY those that have previously been trialed and deemed unresponsive to biologic therapy)
 - Currently on Tier 1* product → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)
 - Currently on Tier 2** product → Fail → Select product from Tier 1 → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)

**NOTE: Patients will not be permitted to switch from Inflectra, Brenzys or Erelzi to another infliximab or etanerecept product listed in Tier 1 and/or 2 if previously trialed and deemed unresponsive to therapy.*


***NOTE: Patients will not be permitted to switch from Remicade or Enbrel to another infliximab or etanerecept product listed in Tier 1 if previously trialed and deemed unresponsive to therapy.*

Special Requests (Case-By-Case)


- To request special consideration for coverage on a case-by-case basis outside of this Policy, the clinician may write to the Provincial Drug Programs Review Committee (PDPRC), based upon the unique circumstances of the patient and alternative treatments tried.
- Additional information on the Provincial Drug Programs Review Process and requirements can be found at:
<https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf>.

Tiered Biologics Reimbursement Policy Flowsheet

New Patients (Biologic-Naïve):



Existing Patients:



**NOTE: Patients will not be permitted to switch from Inflectra, Brenzys or Erelzi to another infliximab or etanercept product listed in Tier 1 and/or 2 if previously trialed and deemed unresponsive to therapy.*

***NOTE: Patients will not be permitted to switch from Remicade or Enbrel to another infliximab or etanercept product listed in Tier 1 if previously trialed and deemed unresponsive to therapy.*

| Tier 1 | | | | | | | |
|--------------|--------------------|---------------------------|-----------------------------|----------------|---------------------------|----------------------|-------------------------|
| Product Name | Generic Name | Rheumatoid Arthritis (RA) | Ankylosing Spondylitis (AS) | Psoriasis (PO) | Psoriatic Arthritis (PsA) | Crohn's Disease (CD) | Ulcerative Colitis (UC) |
| Actemra | tocilizumab | X | | | | | |
| Brenzys | etanercept | X | X | | | | |
| Cimzia | certolizumab pegol | X | X | | X | | |
| Cosentyx | secukinumab | | X | X | X | | |
| Entyvio | vedolizumab | | | | | X | X |
| Erelzi | etanercept | X | X | | | | |
| Humira | adalimumab | | | | | | X |
| Inflectra | infliximab | X | X | X | X | X | X |
| Orencia | abatacept | X | | | | | |
| Rituxan | rituximab | X | | | | | |
| Simponi | golimumab | X | X | | X | | X |
| Simponi IV | golimumab | X | | | | | |
| Taltz | ixekizumab | | | X | | | |
| Xeljanz | tofacitinib | X | | | | | |
| Tier 2 | | | | | | | |
| Enbrel | etanercept | X | X | X | X | | |
| Humira | adalimumab | X | X | X | X | X | |
| Kineret | anakinra | X | | | | | |
| Remicade | infliximab | X | X | X | X | X | X |
| Stelara | ustekinumab | | | X | | | |

- Prescribing Criteria for all products noted above can be found on the online document: Part 3 Exception Drug Status (EDS) here: <https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf>
- For information on Health Canada's review and recommendations, please see: <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
- For Common Drug Review's review and recommendations, please see: <https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr/reports>

Dermatology (Plaque Psoriasis)

| Tier 1 |
|------------------------|
| Cosentyx (secukinumab) |
| Inflectra (infliximab) |
| Taltz (ixekizumab) |
| |
| Tier 2 |
| Enbrel (etanercept) |
| Humira (adalimumab) |
| Remicade (infliximab) |
| Stelara (ustekinumab) |

Gastroenterology (Crohn's Disease)

| Tier 1 |
|------------------------|
| Entyvio (vedolizumab) |
| Inflectra (infliximab) |
| |
| Tier 2 |
| Humira (adalimumab) |
| Remicade (infliximab) |

Gastroenterology (Ulcerative Colitis)

| Tier 1 |
|------------------------|
| Entyvio (vedolizumab) |
| Humira (adalimumab) |
| Inflectra (infliximab) |
| Simponi (golimumab) |
| |
| Tier 2 |
| Remicade (infliximab) |

Rheumatology (Ankylosing Spondylitis)

| Tier 1 |
|-----------------------------|
| Brenzys (etanercept) |
| Cimzia (certolizumab pegol) |
| Cosentyx (secukinumab) |
| Erelzi (etanercept) |
| Inflectra (infliximab) |
| Simponi (golimumab) |
| |
| Tier 2 |
| Enbrel (etanercept) |
| Humira (adalimumab) |
| Remicade (infliximab) |

Rheumatology (Psoriatic Arthritis)

| Tier 1 |
|-----------------------------|
| Cimzia (certolizumab pegol) |
| Cosentyx (secukinumab) |
| Inflectra (infliximab) |
| Simponi (golimumab) |
| |
| Tier 2 |
| Enbrel (etanercept) |
| Humira (adalimumab) |
| Remicade (infliximab) |

Rheumatology (Rheumatoid Arthritis)

| Tier 1 |
|-----------------------------|
| Actemra (tocilizumab) |
| Brenzys (etanercept) |
| Cimzia (certolizumab pegol) |
| Erelzi (etanercept) |
| Inflectra (infliximab) |
| Orencia (abatacept) |
| Rituxan (rituximab) |
| Simponi (golimumab) |
| Simponi IV (golimumab) |
| Xeljanz (tofacitinib) |
| |
| Tier 2 |
| Enbrel (etanercept) |
| Humira (adalimumab) |
| Kineret (anakinra) |
| Remicade (infliximab) |

FREQUENTLY ASKED QUESTIONS

How will this change affect patients?

- The Tiered Biologics Reimbursement Policy will:
 - NOT require patients to switch from their existing therapy (if currently providing the expected response) and
 - ONLY apply to:
 - New patients (biologic-naïve) and
 - Existing patients that have previously been trialed and deemed unresponsive to biologic therapy.
- Prescribers would be required to try two (2) Tier 1 products before prescribing a Tier 2 product.
- Clients and prescribers will continue to have a wide choice over therapeutic selection and if required, clinicians may request special consideration for coverage on a case-by-case basis outside of the Policy via the Provincial Drug Programs Review Committee (PDPRC).

What is a Tier 1 and Tier 2 biologic product?

Tier 1 biologic products (for the indications noted) have been determined to be the most cost-effective agents which allows Pharmacare to achieve greater value for its publicly funded drug programs, treat more patients without increasing expenditures, and retain prescriber/patient choice.

Which biologic products are listed on Tier 1 and Tier 2?

A current list of Tier 1 and Tier 2 products can be found online at: <http://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>
Clients and prescribers will continue to have a wide choice over therapeutic selection.

What if the prescriber would like to use a Tier 2 product before a Tier 1 product which is outside the biologics tiering policy?

Clinicians may request special consideration for coverage on a case-by-case basis outside of the biologics tiering policy via the Provincial Drug Programs Review Committee (PDPRC).

Information on this program can be found here: <https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf>

Pharmacy Line: (204) 786-8000 in Winnipeg or at 1-800-663-7774 outside Winnipeg

Public Inquiries: (204) 786-7141 in Winnipeg or at 1-800-297-8099 outside of Winnipeg TTY (204) 774-8618.

Information is also available at <http://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>